| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 59 | 2025 | 734 | 6.670 |
Why?
|
| Depressive Disorder | 12 | 2017 | 476 | 1.990 |
Why?
|
| Cognition Disorders | 11 | 2022 | 569 | 1.680 |
Why?
|
| Anxiety Disorders | 10 | 2017 | 720 | 1.350 |
Why?
|
| Stress Disorders, Post-Traumatic | 5 | 2023 | 648 | 1.140 |
Why?
|
| Depression | 20 | 2020 | 1339 | 1.070 |
Why?
|
| Psychiatric Status Rating Scales | 15 | 2018 | 848 | 0.940 |
Why?
|
| REM Sleep Behavior Disorder | 2 | 2025 | 17 | 0.940 |
Why?
|
| Anxiety | 13 | 2019 | 991 | 0.880 |
Why?
|
| Mental Disorders | 7 | 2016 | 888 | 0.830 |
Why?
|
| Aggression | 1 | 2024 | 227 | 0.730 |
Why?
|
| Cognitive Dysfunction | 2 | 2022 | 316 | 0.660 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 280 | 0.630 |
Why?
|
| Dementia | 4 | 2014 | 460 | 0.610 |
Why?
|
| Pituitary Neoplasms | 1 | 2020 | 82 | 0.600 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 197 | 0.600 |
Why?
|
| Dystonia | 2 | 2020 | 172 | 0.500 |
Why?
|
| Psychotic Disorders | 4 | 2019 | 150 | 0.480 |
Why?
|
| Veterans | 6 | 2025 | 1760 | 0.480 |
Why?
|
| Cognition | 3 | 2020 | 810 | 0.480 |
Why?
|
| Middle Aged | 43 | 2025 | 28968 | 0.460 |
Why?
|
| Comorbidity | 11 | 2020 | 1604 | 0.440 |
Why?
|
| Aged | 37 | 2025 | 21406 | 0.430 |
Why?
|
| Humans | 79 | 2025 | 132013 | 0.430 |
Why?
|
| Surveys and Questionnaires | 11 | 2018 | 3993 | 0.430 |
Why?
|
| Depressive Disorder, Major | 3 | 2020 | 440 | 0.410 |
Why?
|
| Panic Disorder | 2 | 2011 | 52 | 0.400 |
Why?
|
| Torticollis | 3 | 2021 | 72 | 0.400 |
Why?
|
| Delusions | 2 | 2012 | 19 | 0.390 |
Why?
|
| Hallucinations | 2 | 2012 | 28 | 0.380 |
Why?
|
| Health Services | 1 | 2012 | 70 | 0.380 |
Why?
|
| Health Status | 2 | 2012 | 407 | 0.370 |
Why?
|
| Memory Disorders | 4 | 2020 | 210 | 0.370 |
Why?
|
| Illusions | 1 | 2012 | 8 | 0.370 |
Why?
|
| Drug Utilization | 1 | 2013 | 166 | 0.370 |
Why?
|
| Disclosure | 1 | 2013 | 152 | 0.360 |
Why?
|
| Family Health | 3 | 2011 | 256 | 0.360 |
Why?
|
| Nootropic Agents | 2 | 2009 | 27 | 0.350 |
Why?
|
| Multiple Sclerosis | 1 | 2015 | 383 | 0.350 |
Why?
|
| Male | 49 | 2025 | 64914 | 0.340 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2010 | 34 | 0.330 |
Why?
|
| Ubiquitin-Protein Ligases | 5 | 2014 | 376 | 0.330 |
Why?
|
| Aged, 80 and over | 17 | 2020 | 7105 | 0.320 |
Why?
|
| Antiparkinson Agents | 2 | 2009 | 66 | 0.310 |
Why?
|
| Propylamines | 1 | 2009 | 8 | 0.300 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2009 | 29 | 0.300 |
Why?
|
| Female | 46 | 2025 | 70643 | 0.300 |
Why?
|
| Prevalence | 11 | 2020 | 2655 | 0.290 |
Why?
|
| Dystonic Disorders | 2 | 2021 | 94 | 0.280 |
Why?
|
| Severity of Illness Index | 13 | 2018 | 3088 | 0.260 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2006 | 98 | 0.250 |
Why?
|
| Physical Therapy Modalities | 1 | 2006 | 56 | 0.240 |
Why?
|
| Psychometrics | 6 | 2013 | 687 | 0.230 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2025 | 6 | 0.230 |
Why?
|
| Prodromal Symptoms | 1 | 2025 | 10 | 0.230 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2020 | 229 | 0.220 |
Why?
|
| Alcohol Amnestic Disorder | 1 | 2003 | 2 | 0.210 |
Why?
|
| Neuropsychological Tests | 8 | 2020 | 990 | 0.210 |
Why?
|
| Adult | 23 | 2021 | 31563 | 0.210 |
Why?
|
| Patient Health Questionnaire | 2 | 2020 | 17 | 0.210 |
Why?
|
| Indans | 1 | 2004 | 54 | 0.200 |
Why?
|
| Violence | 1 | 2024 | 128 | 0.200 |
Why?
|
| Cross-Sectional Studies | 11 | 2020 | 3760 | 0.200 |
Why?
|
| Psychotropic Drugs | 3 | 2011 | 129 | 0.190 |
Why?
|
| HIV Infections | 1 | 2015 | 2047 | 0.190 |
Why?
|
| Mental Health Services | 3 | 2015 | 269 | 0.190 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2016 | 691 | 0.190 |
Why?
|
| Piperidines | 1 | 2004 | 235 | 0.180 |
Why?
|
| Alzheimer Disease | 4 | 2015 | 857 | 0.180 |
Why?
|
| Memory | 3 | 2020 | 356 | 0.180 |
Why?
|
| Hippocampus | 2 | 2020 | 817 | 0.170 |
Why?
|
| Pilot Projects | 5 | 2025 | 1441 | 0.170 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2020 | 9 | 0.160 |
Why?
|
| Attention | 2 | 2020 | 199 | 0.160 |
Why?
|
| Neoplasms | 1 | 2015 | 2956 | 0.160 |
Why?
|
| Parasomnias | 1 | 2019 | 4 | 0.160 |
Why?
|
| Internationality | 1 | 2020 | 133 | 0.160 |
Why?
|
| Unconsciousness | 1 | 2019 | 18 | 0.160 |
Why?
|
| Combat Disorders | 1 | 2019 | 22 | 0.160 |
Why?
|
| Dreams | 1 | 2019 | 23 | 0.150 |
Why?
|
| Fatigue | 3 | 2010 | 201 | 0.150 |
Why?
|
| Tremor | 1 | 2020 | 136 | 0.150 |
Why?
|
| Encephalitis | 1 | 2020 | 118 | 0.150 |
Why?
|
| Activities of Daily Living | 3 | 2015 | 428 | 0.150 |
Why?
|
| Evaluation Studies as Topic | 2 | 2008 | 258 | 0.140 |
Why?
|
| Sleep | 1 | 2021 | 374 | 0.140 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 101 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2015 | 767 | 0.140 |
Why?
|
| Interview, Psychological | 1 | 2018 | 108 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 143 | 0.130 |
Why?
|
| Brain Concussion | 1 | 2019 | 238 | 0.130 |
Why?
|
| Phenotype | 3 | 2021 | 4526 | 0.130 |
Why?
|
| Public Housing | 1 | 2016 | 7 | 0.120 |
Why?
|
| Substance-Related Disorders | 2 | 2018 | 491 | 0.120 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 302 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3412 | 0.120 |
Why?
|
| Age of Onset | 6 | 2014 | 622 | 0.120 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 161 | 0.120 |
Why?
|
| Psychiatry | 1 | 2019 | 272 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2010 | 3352 | 0.120 |
Why?
|
| Apathy | 1 | 2015 | 10 | 0.120 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 254 | 0.110 |
Why?
|
| Motor Skills Disorders | 2 | 2014 | 9 | 0.110 |
Why?
|
| Mass Screening | 1 | 2020 | 828 | 0.110 |
Why?
|
| Epilepsy | 1 | 2002 | 889 | 0.110 |
Why?
|
| Analysis of Variance | 4 | 2016 | 1011 | 0.110 |
Why?
|
| Heterozygote | 3 | 2014 | 713 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 232 | 0.100 |
Why?
|
| ROC Curve | 2 | 2020 | 600 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2011 | 1254 | 0.100 |
Why?
|
| Research Design | 2 | 2015 | 742 | 0.100 |
Why?
|
| Movement | 1 | 2014 | 168 | 0.100 |
Why?
|
| Role | 1 | 2013 | 29 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2016 | 425 | 0.100 |
Why?
|
| Mental Health | 2 | 2014 | 370 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 1160 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 237 | 0.090 |
Why?
|
| Schizophrenia | 1 | 2015 | 332 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2013 | 195 | 0.090 |
Why?
|
| Diagnosis, Differential | 4 | 2007 | 1957 | 0.090 |
Why?
|
| Mutation | 4 | 2010 | 6226 | 0.090 |
Why?
|
| Convergence, Ocular | 1 | 2011 | 2 | 0.090 |
Why?
|
| Dopamine Agents | 1 | 2011 | 29 | 0.090 |
Why?
|
| Independent Living | 1 | 2012 | 70 | 0.090 |
Why?
|
| Point Mutation | 2 | 2010 | 349 | 0.090 |
Why?
|
| Ocular Motility Disorders | 1 | 2011 | 38 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 2013 | 269 | 0.090 |
Why?
|
| Oculomotor Muscles | 1 | 2011 | 68 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 327 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2020 | 6568 | 0.090 |
Why?
|
| Database Management Systems | 1 | 2010 | 30 | 0.080 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2010 | 36 | 0.080 |
Why?
|
| Societies, Scientific | 1 | 2010 | 25 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2013 | 492 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 3 | 2005 | 1133 | 0.080 |
Why?
|
| Comparative Effectiveness Research | 1 | 2010 | 72 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2010 | 76 | 0.080 |
Why?
|
| Glucosylceramidase | 1 | 2010 | 27 | 0.080 |
Why?
|
| alpha-Synuclein | 3 | 2005 | 129 | 0.080 |
Why?
|
| United States | 6 | 2019 | 11655 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 726 | 0.080 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 15 | 0.080 |
Why?
|
| Quality of Life | 5 | 2021 | 2157 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 698 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 198 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2015 | 793 | 0.070 |
Why?
|
| Genetic Counseling | 1 | 2010 | 245 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1168 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2009 | 94 | 0.070 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2008 | 7 | 0.070 |
Why?
|
| Substantia Nigra | 1 | 2008 | 35 | 0.070 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 34 | 0.070 |
Why?
|
| Lewy Body Disease | 2 | 2004 | 20 | 0.070 |
Why?
|
| Movement Disorders | 1 | 2010 | 223 | 0.070 |
Why?
|
| Caregivers | 1 | 2013 | 588 | 0.070 |
Why?
|
| Prefrontal Cortex | 1 | 2009 | 218 | 0.060 |
Why?
|
| Education | 1 | 2007 | 111 | 0.060 |
Why?
|
| MEDLINE | 1 | 2006 | 20 | 0.060 |
Why?
|
| Adrenergic Agonists | 1 | 2006 | 11 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2020 | 5166 | 0.060 |
Why?
|
| Stroke | 1 | 2014 | 1081 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2020 | 1230 | 0.060 |
Why?
|
| Motivation | 1 | 2008 | 330 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2016 | 12987 | 0.060 |
Why?
|
| Young Adult | 5 | 2020 | 9952 | 0.060 |
Why?
|
| Deep Brain Stimulation | 1 | 2011 | 432 | 0.060 |
Why?
|
| Emotions | 1 | 2008 | 367 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2006 | 98 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1177 | 0.060 |
Why?
|
| Bipolar Disorder | 1 | 2009 | 369 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 356 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2006 | 161 | 0.060 |
Why?
|
| Plaque, Amyloid | 1 | 2004 | 69 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3137 | 0.050 |
Why?
|
| Mammillary Bodies | 1 | 2003 | 2 | 0.050 |
Why?
|
| Diencephalon | 1 | 2003 | 10 | 0.050 |
Why?
|
| Risk | 2 | 2020 | 761 | 0.050 |
Why?
|
| Consensus | 1 | 2007 | 649 | 0.050 |
Why?
|
| Polysomnography | 1 | 2025 | 155 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2004 | 141 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 3008 | 0.050 |
Why?
|
| Genetic Testing | 4 | 2010 | 1099 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 703 | 0.050 |
Why?
|
| Age Factors | 3 | 2018 | 2911 | 0.050 |
Why?
|
| Cerebellar Diseases | 1 | 2002 | 81 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 481 | 0.040 |
Why?
|
| Huntington Disease | 1 | 2002 | 143 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2004 | 470 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2005 | 800 | 0.040 |
Why?
|
| Synucleins | 3 | 2005 | 15 | 0.040 |
Why?
|
| Aging | 1 | 2008 | 1249 | 0.040 |
Why?
|
| Neurons | 2 | 2008 | 2002 | 0.040 |
Why?
|
| International Cooperation | 2 | 2011 | 166 | 0.040 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2 | 2010 | 20 | 0.040 |
Why?
|
| Genotype | 3 | 2010 | 2697 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 436 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1656 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 311 | 0.040 |
Why?
|
| Simplexvirus | 1 | 2020 | 100 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2019 | 120 | 0.040 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2019 | 128 | 0.040 |
Why?
|
| Risk Factors | 4 | 2015 | 10931 | 0.040 |
Why?
|
| Vision, Ocular | 1 | 2020 | 131 | 0.040 |
Why?
|
| Community Mental Health Services | 1 | 2019 | 39 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2010 | 749 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 426 | 0.040 |
Why?
|
| Adolescent | 4 | 2020 | 20544 | 0.040 |
Why?
|
| Probability | 1 | 2018 | 322 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 172 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 351 | 0.030 |
Why?
|
| Disease Progression | 2 | 2014 | 2226 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2139 | 0.030 |
Why?
|
| Telephone | 1 | 2015 | 123 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 549 | 0.030 |
Why?
|
| Nurses | 1 | 2015 | 74 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 198 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 457 | 0.030 |
Why?
|
| Touch | 1 | 2014 | 39 | 0.030 |
Why?
|
| Electromyography | 1 | 2014 | 141 | 0.030 |
Why?
|
| Posture | 1 | 2014 | 144 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2014 | 192 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 453 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 819 | 0.020 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 20 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2013 | 208 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 3843 | 0.020 |
Why?
|
| Carbidopa | 1 | 2011 | 17 | 0.020 |
Why?
|
| Sensation | 1 | 2011 | 51 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2015 | 569 | 0.020 |
Why?
|
| Levodopa | 1 | 2011 | 94 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1500 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 1380 | 0.020 |
Why?
|
| Syndrome | 1 | 2013 | 1174 | 0.020 |
Why?
|
| Brain | 3 | 2010 | 3182 | 0.020 |
Why?
|
| Jews | 1 | 2010 | 34 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1351 | 0.020 |
Why?
|
| Decision Making | 1 | 2015 | 700 | 0.020 |
Why?
|
| Visual Perception | 1 | 2010 | 133 | 0.020 |
Why?
|
| Executive Function | 1 | 2010 | 126 | 0.020 |
Why?
|
| Cell Line | 2 | 2005 | 2725 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 277 | 0.020 |
Why?
|
| Telemedicine | 1 | 2015 | 494 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 795 | 0.020 |
Why?
|
| Physicians | 1 | 2015 | 640 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 191 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 823 | 0.020 |
Why?
|
| Hospitals | 1 | 2011 | 438 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1294 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2008 | 79 | 0.020 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2007 | 13 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2011 | 707 | 0.020 |
Why?
|
| Publishing | 1 | 2007 | 106 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 1457 | 0.010 |
Why?
|
| Lewy Bodies | 1 | 2004 | 12 | 0.010 |
Why?
|
| Formates | 1 | 2004 | 8 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 1839 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2005 | 83 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 636 | 0.010 |
Why?
|
| MPTP Poisoning | 1 | 2004 | 3 | 0.010 |
Why?
|
| Nitric Oxide Donors | 1 | 2004 | 20 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2004 | 38 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 173 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 422 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2311 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2004 | 179 | 0.010 |
Why?
|
| Cell Death | 1 | 2004 | 242 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 356 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1579 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 804 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 1580 | 0.010 |
Why?
|
| tau Proteins | 1 | 2004 | 236 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2010 | 17374 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 996 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 574 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1710 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1350 | 0.010 |
Why?
|
| Animals | 3 | 2007 | 34804 | 0.010 |
Why?
|
| Personality Disorders | 1 | 2002 | 169 | 0.010 |
Why?
|
| Prognosis | 1 | 2009 | 5008 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 2447 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 3043 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 1047 | 0.010 |
Why?
|
| Mice | 2 | 2005 | 18478 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 3865 | 0.010 |
Why?
|